Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have received a consensus recommendation of “Moderate Buy” from the seventeen research firms that are currently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $215.88.

A number of analysts have recently weighed in on ALNY shares. The Goldman Sachs Group cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the company from $230.00 to $173.00 in a report on Friday, February 16th. Royal Bank of Canada restated an “outperform” rating and issued a $235.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Wolfe Research initiated coverage on Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They set a “peer perform” rating on the stock. Chardan Capital lowered their price objective on Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating for the company in a research report on Friday, February 16th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $165.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th.

Alnylam Pharmaceuticals Stock Up 2.8 %

Alnylam Pharmaceuticals stock opened at $147.36 on Tuesday. The firm has a market cap of $18.56 billion, a P/E ratio of -41.39 and a beta of 0.39. The business has a fifty day moving average of $150.21 and a two-hundred day moving average of $165.76. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million for the quarter, compared to analysts’ expectations of $439.38 million. During the same quarter last year, the company earned ($1.68) earnings per share. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. Equities analysts expect that Alnylam Pharmaceuticals will post -4.46 earnings per share for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Allspring Global Investments Holdings LLC raised its position in Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares during the last quarter. Commonwealth Equity Services LLC raised its holdings in shares of Alnylam Pharmaceuticals by 32.3% during the first quarter. Commonwealth Equity Services LLC now owns 5,594 shares of the biopharmaceutical company’s stock worth $836,000 after purchasing an additional 1,365 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Alnylam Pharmaceuticals by 36.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 35,822 shares of the biopharmaceutical company’s stock worth $5,354,000 after purchasing an additional 9,662 shares during the last quarter. Prestige Wealth Management Group LLC lifted its position in Alnylam Pharmaceuticals by 69.8% during the first quarter. Prestige Wealth Management Group LLC now owns 472 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 194 shares during the period. Finally, Yousif Capital Management LLC boosted its holdings in Alnylam Pharmaceuticals by 9.7% in the first quarter. Yousif Capital Management LLC now owns 1,635 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 144 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.